About Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PTIE
CUSIP69562K10
Phone512-501-2444
Debt
Debt-to-Equity RatioN/A
Current Ratio9.43%
Quick Ratio9.43%
Price-To-Earnings
Trailing P/E Ratio-4.31
Forward P/E Ratio-4.76
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.47 per share
Price / Book5.34
Profitability
EPS (Most Recent Fiscal Year)($1.82)
Net Income$-11,910,000.00
Net MarginsN/A
Return on Equity-93.35%
Return on Assets-86.53%
Miscellaneous
Employees9
Outstanding Shares6,900,000
Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions
What is Pain Therapeutics' stock symbol?
Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."
When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?
Pain Therapeutics's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.
How were Pain Therapeutics' earnings last quarter?
Pain Therapeutics, Inc (NASDAQ:PTIE) issued its earnings results on Monday, February, 5th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter. View Pain Therapeutics' Earnings History.
When is Pain Therapeutics' next earnings date?
Who are some of Pain Therapeutics' key competitors?
Some companies that are related to Pain Therapeutics include Leap Therapeutics (LPTX), Cumberland Pharmaceuticals (CPIX), Oramed Pharmaceuticals (ORMP), Forward Pharma (FWP), RedHill Biopharma (RDHL), Aileron Therapeutics (ALRN), KalVista Pharmaceuticals (KALV), Alpine Immune Sciences (ALPN), Columbia Laboratories (JNP), Flex Pharma (FLKS), Agile Therapeutics (AGRX), Aralez Pharmaceuticals (ARLZ), Trillium Therapeutics (TRIL), Sunesis Pharmaceuticals (SNSS), Ophthotech (OPHT), KemPharm (KMPH), Galmed Pharmaceuticals (GLMD) and BioLineRx (BLRX).
Who are Pain Therapeutics' key executives?
Pain Therapeutics' management team includes the folowing people:
- Mr. Remi Barbier, Founder, Chairman, CEO, Pres & Principal Financial Officer (Age 58)
- Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 75)
- Mr. Michael J. O'Donnell, Sec. & Director (Age 60)
- Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs
Has Pain Therapeutics been receiving favorable news coverage?
News coverage about PTIE stock has trended positive recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.36 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 48.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Pain Therapeutics?
Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pain Therapeutics' stock price today?
One share of PTIE stock can currently be purchased for approximately $7.85.
How big of a company is Pain Therapeutics?
Pain Therapeutics has a market capitalization of $55.10 million. The biopharmaceutical company earns $-11,910,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Pain Therapeutics employs 9 workers across the globe.
How can I contact Pain Therapeutics?
Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444.
MarketBeat Community Rating for Pain Therapeutics (PTIE)
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pain Therapeutics (NASDAQ:PTIE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Pain Therapeutics in the last 12 months. There are currently 1 sell rating for the stock, resulting in a consensus rating of "Sell."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Sell | Sell | Sell | Sell |
Consensus Rating Score: | 1.00 | 1.00 | 1.00 | 1.00 |
Ratings Breakdown: | 1 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s) | 1 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s) | 1 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s) | 1 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s) |
Consensus Price Target: | N/A | N/A | N/A | N/A |
Price Target Upside: | N/A | N/A | N/A | N/A |
Pain Therapeutics (NASDAQ:PTIE) Consensus Price Target History

Pain Therapeutics (NASDAQ:PTIE) Analyst Ratings History
Show:
Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
---|
7/17/2017 | Gabelli | Downgrade | Hold -> Sell | | Low |  |
(Data available from 4/20/2016 forward)
Pain Therapeutics (NASDAQ:PTIE) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
12/11/2012 | special | $5.25 | | 12/13/2012 | 12/17/2012 | 12/24/2012 |
(Data available from 1/1/2013 forward)
Pain Therapeutics (NASDAQ PTIE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 31.40%
Institutional Ownership Percentage: 33.78%
Pain Therapeutics (NASDAQ PTIE) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
11/6/2013 | Sanford Robertson | Director | Buy | 50,000 | $3.73 | $186,500.00 | 369,727 | |
(Data available from 1/1/2013 forward)
Pain Therapeutics (NASDAQ PTIE) News Headlines
Source: |
|
Date | Headline |
---|
 | Pain Therapeutics (PTIE) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 18 at 11:44 AM |
 | Gabelli Downgrades Pain Therapeutics (PTIE) to Sell www.americanbankingnews.com - April 17 at 11:28 PM |
 | Pain Therapeutics (PTIE) Shares March Higher, Can It Continue? finance.yahoo.com - April 12 at 5:44 PM |
 | Acclaimed Scientists and Physicians Join the Scientific Advisory Board of SiteOne Therapeutics to Help Guide the ... www.prnewswire.com - April 6 at 8:03 AM |
 | Pain Therapeutics (PTIE) Raised to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 3 at 9:18 PM |
 | Post-Operative Pain Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years: P&S ... globenewswire.com - March 31 at 5:40 PM |
 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Pain Therapeutics, Inc. for Potential Breaches ... - PR Newswire (press release) www.prnewswire.com - March 21 at 8:06 AM |
 | Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY ER® - GlobeNewswire (press release) globenewswire.com - March 20 at 8:02 AM |
 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Pain Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors www.prnewswire.com - March 19 at 7:49 AM |
 | Pain Therapeutics (PTIE) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - March 14 at 6:48 AM |
 | Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors finance.yahoo.com - March 6 at 5:32 PM |
 | Pain Therapeutics (PTIE) Downgraded by ValuEngine www.americanbankingnews.com - March 4 at 11:38 AM |
 | Pain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date - StreetInsider.com www.streetinsider.com - March 3 at 5:36 PM |
 | Pain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date www.streetinsider.com - March 2 at 8:23 AM |
 | How Should You Think About Pain Therapeutics Inc’s (NASDAQ:PTIE) Risks? finance.yahoo.com - March 1 at 5:46 PM |
 | FDA Accepts REMOXY® NDA for Review, Sets PDUFA Date of August 7, 2018 finance.yahoo.com - March 1 at 8:30 AM |
 | Pain Therapeutics (PTIE) Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - February 24 at 4:30 PM |
 | Pain Therapeutics (PTIE) Upgraded at Zacks Investment Research www.americanbankingnews.com - February 22 at 9:56 AM |
 | Gabelli Weighs in on Pain Therapeutics, Inc.'s FY2018 Earnings (PTIE) www.americanbankingnews.com - February 16 at 11:18 AM |
 | Gabelli Comments on Pain Therapeutics, Inc.'s FY2022 Earnings (PTIE) www.americanbankingnews.com - February 15 at 4:28 PM |
 | TTPH Implodes On IGNITE3, EC Approves 2nd Herceptin Biosimilar, PTIE At It Again - Nasdaq www.nasdaq.com - February 14 at 3:34 PM |
 | Pain Therapeutics (PTIE) Resubmits NDA for REMOXY ER - StreetInsider.com www.streetinsider.com - February 14 at 7:38 AM |
 | Pain Therapeutics Resubmits New Drug Application for REMOXY® ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain finance.yahoo.com - February 13 at 3:30 PM |
 | Pain Therapeutics refiles U.S. marketing application for Remoxy ER; shares up 3% seekingalpha.com - February 13 at 9:57 AM |
 | Pain Therapeutics (PTIE) to Release Quarterly Earnings on Thursday www.americanbankingnews.com - February 8 at 1:24 AM |
 | Pain Therapeutics Reports 2017 Financial Results and Corporate Update - GlobeNewswire (press release) globenewswire.com - February 6 at 7:22 AM |
 | Pain Therapeutics Reports 2017 Financial Results and Corporate Update finance.yahoo.com - February 5 at 3:29 PM |
 | Quotidian Technical Highlights on Selected Biotech Stocks -- PDL BioPharma, Progenics Pharma, Pain Therapeutics, and uniQure www.bizjournals.com - January 19 at 11:38 AM |
 | Gabelli Analysts Raise Earnings Estimates for Pain Therapeutics, Inc. (PTIE) www.americanbankingnews.com - January 12 at 6:54 AM |
 | Zacks: Pain Therapeutics, Inc. (PTIE) Given Average Rating of "Strong Sell" by Brokerages www.americanbankingnews.com - January 10 at 5:30 PM |
 | Earnings Growth Hamper Pain Therapeutics (PTIE) Rating investorplace.com - January 10 at 11:18 AM |
 | PTIE Skyrockets On Remoxy Data, ASND On An Ascent, There Is HOPE For GBT www.finanznachrichten.de - January 10 at 10:17 AM |
 | Does Pain Therapeutics Inc’s (NASDAQ:PTIE) Earnings Growth Make It An Outperformer? finance.yahoo.com - January 10 at 10:17 AM |
 | Pain Therapeutics, REMOXY Gets Positive Study Results, Updates for FENROCK and PTI-125 finance.yahoo.com - January 10 at 10:17 AM |
 | Here’s What’s Moving Axsome Therapeutics and Pain Therapeutics finance.yahoo.com - January 10 at 10:17 AM |
 | 2 Biotech Stocks Climbing on Positive Findings - Baystreet.ca www.baystreet.ca - January 9 at 4:46 PM |
 | Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet - Benzinga www.benzinga.com - January 9 at 4:46 PM |
 | Pain Therapeutics Shares Double On Clinical Study Data - Benzinga www.benzinga.com - January 9 at 4:46 PM |
 | 2 Biotech Stocks Climbing on Positive Findings finance.yahoo.com - January 9 at 4:46 PM |
 | Why Pain Therapeutics, Inc. (PTIE) Shares Skyrocketed 150% Today finance.yahoo.com - January 9 at 4:46 PM |
 | Healthcare Stocks Breakout: Pain Therapeutics, Inc. (PTIE), Global Blood Therapeutics Inc (GBT) finance.yahoo.com - January 9 at 4:46 PM |
 | Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet feeds.benzinga.com - January 9 at 3:31 PM |
 | Durect up 11% on Pain Therapeutics' Remoxy-stoked rally seekingalpha.com - January 9 at 12:56 PM |
 | Pain Therapeutics Shares Double On Clinical Study Data feeds.benzinga.com - January 9 at 12:32 PM |
 | Pain Therapeutics Reports Positive Top-line Results from Nasal Abuse Potential Study with REMOXY™ finance.yahoo.com - January 9 at 10:07 AM |
 | Pain Therapeutics (PTIE) versus Its Peers Head-To-Head Review www.americanbankingnews.com - December 28 at 12:16 AM |
 | Zacks Investment Research Lowers Pain Therapeutics (PTIE) to Hold www.americanbankingnews.com - December 27 at 6:24 AM |
 | Pain Therapeutics Reports Positive Regulatory Meeting for REMOXY™ - GlobeNewswire (press release) globenewswire.com - December 19 at 4:39 PM |
 | Pain Therapeutics (PTIE) Announces Positive Regulatory Meeting for REMOXY - StreetInsider.com www.streetinsider.com - December 18 at 4:40 PM |
 | Health Care Sector Update for 12/18/2017: ADRO,PTIE,NVIV - Nasdaq www.nasdaq.com - December 18 at 4:40 PM |
Pain Therapeutics (NASDAQ:PTIE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pain Therapeutics (NASDAQ:PTIE) Income Statement, Balance Sheet and Cash Flow Statement
Pain Therapeutics (NASDAQ PTIE) Stock Chart for Friday, April, 20, 2018
Loading chart…